08:37 AM EDT, 10/27/2025 (MT Newswires) -- Elicio Therapeutics ( ELTX ) said Monday that preliminary analysis from its phase 2 trial indicated that 99% of patients assessed for Human Leukocyte Antigen background induced mKRAS-specific T cell responses after treatment with ELI-002 7P.

The induction of mKRAS-specific T cell responses suggest that ELI-002 7P may address a broad patient population with high unmet need for pancreatic ductal adenocarcinoma, Elicio Therapeutics ( ELTX ) said.

Elicio's ELI-002 7P (seven-peptide formulation) is designed to provide immune response coverage in patients with mKRAS-driven pancreatic cancer, the company said.

Shares of the company were up over 5% in recent Monday premarket activity.